Brought to you by 
MediciNova licenses Kyorin's ibudilast for MS
10 Aug 2005
Executive Summary
Kyorin has granted MediciNova exclusive worldwide rights (excluding Japan, China, Taiwan and South Korea) to develop and commercialize its ibudilast, now known as MN166, for all multiple sclerosis indications except ophthalmic solution formulations. MediciNova also gets rights to sublicense the compound.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MediciNova licenses Kyorin's ibudilast for MS
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice